FDA approves Novartis high blood pressure drug Tekturna

The FDA gave Novartis AG clearance to market its Tekturna drug to treat high blood pressure, breathing new life into a product the firm had almost given up on seven years ago. Developed with Speedel Holding AG, the drug at one time was considered too expensive to make but now emerges as the first new type of drug in more than a decade for treating high blood pressure.

View Full Article in:

Bloomberg Businessweek · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY